skip to main content

MS Spasticity – Nabiximols — SCE Neurology MCQ

Instant feedback + full explanation. One question, done properly.

ModerateMultiple Sclerosis & CNS InflammationMS Spasticity – NabiximolsSCE Neurology

A 50-year-old man with known MS has progressive lower limb spasticity. He is on baclofen 25 mg TDS, which is partially effective. He asks about nabiximols (Sativex) for spasticity. What is the NICE/NHS England position on nabiximols for MS spasticity?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Nabiximols is recommended as an add-on treatment for moderate-to-severe spasticity in MS that has not responded adequately to other pharmacological treatments, subject to a 4-week trial

Nabiximols (Sativex — oromucosal spray containing THC and CBD) is approved as an add-on treatment for moderate-to-severe MS spasticity that has not responded adequately to other anti-spasticity medications. NICE TA972 (2019) and NHS England commissioning guidelines recommend a 4-week trial: if the patient achieves ≥20% improvement on a spasticity numeric rating scale, treatment is continued; if not, it is discontinued. It requires specialist prescribing. A: It is not first-line. C: It is licensed for MS spasticity. D: It is a prescription-only medicine. E: It is an add-on, not a replacement.

Reference: NICE TA972 Nabiximols (2019); NHS England Commissioning Guidance